ArticleFrontiers in oncology2022

Efficacy and Safety for the Use of Half-Dosed Pegylated Granulocyte Colony-Stimulating Factors in Preventing Febrile Neutropenia During Chemotherapy in Patients With Malignant Tumors: A Multicenter, Open-Labeled, Single-Arm Phase 2 Trial.

Qi Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.